tetano
Editor, Senior Moderator
Comput Biol Med
. 2021 May 15;134:104495.
doi: 10.1016/j.compbiomed.2021.104495. Online ahead of print.
Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD
Arushi Chauhan[SUP] 1 [/SUP], Pramod Avti[SUP] 2 [/SUP], Nishant Shekhar[SUP] 3 [/SUP], Manisha Prajapat[SUP] 3 [/SUP], Phulen Sarma[SUP] 3 [/SUP], Anusuya Bhattacharyya[SUP] 4 [/SUP], Subodh Kumar[SUP] 3 [/SUP], Hardeep Kaur[SUP] 3 [/SUP], Ajay Prakash[SUP] 3 [/SUP], Bikash Medhi[SUP] 5 [/SUP]
Affiliations
Abstract
The advent of SARS-CoV-2 has become a universal health issue with no appropriate cure available to date. The coronavirus nucleocapsid (N) protein combines viral genomic RNA into a ribonucleoprotein and protects the viral genome from the host's nucleases. Structurally, the N protein comprises two independent domains: the N-terminal domain (NTD) for RNA-binding and C-terminal domain (CTD) involved in RNA-binding, protein dimerization, and nucleocapsid stabilization. The present study explains the structural aspects associated with the involvement of nucleocapsid C-terminal domain in the subunit assembly that helps the RNA binding and further stabilizing the virus assembly by protecting RNA from the hosts exonucleases degradation. The molecular dynamics (MD) simulations of the N-CTD and RNA complex suggests two active sites (site I: a monomer) and (site II: a dimer) with structural stability (RMSD: ~2 ?), C? fluctuations (RMSF: ~3 ?) and strong protein-ligand interactions were estimated through the SiteMap module of Schrodinger. Virtual screening of 2456 FDA-approved drugs using structure-based docking identified top two leads distinctively against Site-I (monomer): Ceftaroline fosamil (MM-GBSA = -47.12 kcal/mol) and Cefoperazone (-45.84 kcal/mol); and against Site-II (dimer): Boceprevir, (an antiviral protease inhibitor, -106.78 kcal/mol) and Ceftaroline fosamil (-99.55 kcal/mol). The DCCM and PCA of drugs Ceftaroline fosamil (PC1+PC2 = 71.9%) and Boceprevir (PC1 +PC2 = 61.6%) show significant correlated residue motions which suggests highly induced conformational changes in the N-CTD dimer. Therefore, we propose N-CTD as a druggable target with two active binding sites (monomer and dimer) involved in specific RNA binding and stability. The RNA binding site with Ceftaroline fosamil binding can prevent viral assembly and can act as an antiviral for coronavirus.
Keywords: Dynamic cross-correlation matrix (DCCM); Molecular dynamics (MD); Molecular mechanics/generalized born model and solvent accessibility (MM/GBSA); Nucleocapsid C terminal domain (N-CTD); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2021 May 15;134:104495.
doi: 10.1016/j.compbiomed.2021.104495. Online ahead of print.
Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD
Arushi Chauhan[SUP] 1 [/SUP], Pramod Avti[SUP] 2 [/SUP], Nishant Shekhar[SUP] 3 [/SUP], Manisha Prajapat[SUP] 3 [/SUP], Phulen Sarma[SUP] 3 [/SUP], Anusuya Bhattacharyya[SUP] 4 [/SUP], Subodh Kumar[SUP] 3 [/SUP], Hardeep Kaur[SUP] 3 [/SUP], Ajay Prakash[SUP] 3 [/SUP], Bikash Medhi[SUP] 5 [/SUP]
Affiliations
- PMID: 34022485
- DOI: 10.1016/j.compbiomed.2021.104495
Abstract
The advent of SARS-CoV-2 has become a universal health issue with no appropriate cure available to date. The coronavirus nucleocapsid (N) protein combines viral genomic RNA into a ribonucleoprotein and protects the viral genome from the host's nucleases. Structurally, the N protein comprises two independent domains: the N-terminal domain (NTD) for RNA-binding and C-terminal domain (CTD) involved in RNA-binding, protein dimerization, and nucleocapsid stabilization. The present study explains the structural aspects associated with the involvement of nucleocapsid C-terminal domain in the subunit assembly that helps the RNA binding and further stabilizing the virus assembly by protecting RNA from the hosts exonucleases degradation. The molecular dynamics (MD) simulations of the N-CTD and RNA complex suggests two active sites (site I: a monomer) and (site II: a dimer) with structural stability (RMSD: ~2 ?), C? fluctuations (RMSF: ~3 ?) and strong protein-ligand interactions were estimated through the SiteMap module of Schrodinger. Virtual screening of 2456 FDA-approved drugs using structure-based docking identified top two leads distinctively against Site-I (monomer): Ceftaroline fosamil (MM-GBSA = -47.12 kcal/mol) and Cefoperazone (-45.84 kcal/mol); and against Site-II (dimer): Boceprevir, (an antiviral protease inhibitor, -106.78 kcal/mol) and Ceftaroline fosamil (-99.55 kcal/mol). The DCCM and PCA of drugs Ceftaroline fosamil (PC1+PC2 = 71.9%) and Boceprevir (PC1 +PC2 = 61.6%) show significant correlated residue motions which suggests highly induced conformational changes in the N-CTD dimer. Therefore, we propose N-CTD as a druggable target with two active binding sites (monomer and dimer) involved in specific RNA binding and stability. The RNA binding site with Ceftaroline fosamil binding can prevent viral assembly and can act as an antiviral for coronavirus.
Keywords: Dynamic cross-correlation matrix (DCCM); Molecular dynamics (MD); Molecular mechanics/generalized born model and solvent accessibility (MM/GBSA); Nucleocapsid C terminal domain (N-CTD); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).